Person: KAYA, HANDAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KAYA
First Name
HANDAN
Name
15 results
Search Results
Now showing 1 - 10 of 15
Publication Metadata only Neoadjuvan kemoterapi uygulanan meme kanserli olgularda güvenli tümör-meme ucu mesafesini meme MR öngörebilir mi?(2022-02-24) UĞURLU, MUSTAFA ÜMİT; AKMERCAN, AHMET; BUĞDAYCI, ONUR; KAYA, HANDAN; AKOĞLU, HALDUN; GÜLLÜOĞLU, MAHMUT BAHADIR; UĞURLU M. Ü., AKMERCAN A., BUĞDAYCI O., KAYA H., AKIN TELLİ T., AKOĞLU H., GÜLLÜOĞLU M. B.Publication Metadata only Myoepithelial differentiation in breast carcinoma(Il Pensiero Scientifico Editore s.r.l., 2008) KAYA, HANDAN; Kaya H., Güllüoǧlu B., Aribal E.Background. The aim of presenting this work is to describe a matrix producing carcinoma with anaplastic myoepithelial cell foci, with the coexistence of in situ myoepithelial carcinoma which originated from a sclerosing adenosis. Case report. A 51-year-old perimenopausal woman presented with a hard irregular lump in her left breast. After histological confirmation of malignancy, the patient underwent a modified radical mastectomy. The tumor was composed of a sclerosed fibroadenoma and preexisting sclerosing adenosis with poorly differentiated overt carcinoma within the cartilaginous matrix. There were foci of ordinary, intermediate-grade carcinoma in situ and myoepithelial carcinoma in situ. Results. We performed immunohistochemistry by the streptavidin-biotin horseradish peroxidase method. Estrogen receptor and progesterone receptor were negative, and so was c-erbB-2. Both the invasive and the in situ components were positive for CK7, CK19, CK14, vimentin, smooth muscle actin, nerve growth factor receptor, and epidermal growth factor receptor. By contrast, CK5/6 immunoexpression was found only in me in situ component. Negativity was found for p63 and CD10 within the tumor. While cytoplasmic bcl-2 immunoexpression was detected in some of the tumor cells of the invasive component, intranuclear p53 expression was found to be positive not only in the invasive component but also in the in situ component of the tumor. Conclusion. The histopathological findings and the immunohistochemistry results support the derivation of the tumor from myoepithelial cells.Publication Open Access Identification of Differentially Expressed IGFBP5-Related Genes in Breast Cancer Tumor Tissues Using cDNA Microarray Experiments(MDPI AG, 2015-11-10) GÜLLÜ AMURAN, GÖKÇE; Akkiprik, Mustafa; Peker, Irem; Ozmen, Tolga; Amuran, Gokce Gullu; Gulluoglu, Bahadir M.; Kaya, Handan; Ozer, AyseIGFBP5 is an important regulatory protein in breast cancer progression. We tried to identify differentially expressed genes (DEGs) between breast tumor tissues with IGFBP5 overexpression and their adjacent normal tissues. In this study, thirty-eight breast cancer and adjacent normal breast tissue samples were used to determine IGFBP5 expression by qPCR. cDNA microarrays were applied to the highest IGFBP5 overexpressed tumor samples compared to their adjacent normal breast tissue. Microarray analysis revealed that a total of 186 genes were differentially expressed in breast cancer compared with normal breast tissues. Of the 186 genes, 169 genes were downregulated and 17 genes were upregulated in the tumor samples. KEGG pathway analyses showed that protein digestion and absorption, focal adhesion, salivary secretion, drug metabolism-cytochrome P450, and phenylalanine metabolism pathways are involved. Among these DEGs, the prominent top two genes (MMP11 and COL1A1) which potentially correlated with IGFBP5 were selected for validation using real time RT-qPCR. Only COL1A1 expression showed a consistent upregulation with IGFBP5 expression and COL1A1 and MMP11 were significantly positively correlated. We concluded that the discovery of coordinately expressed genes related with IGFBP5 might contribute to understanding of the molecular mechanism of the function of IGFBP5 in breast cancer. Further functional studies on DEGs and association with IGFBP5 may identify novel biomarkers for clinical applications in breast cancer.Publication Metadata only Meme kanserinde neoadjuvan kemoterapi sonrası es-zamani: Rekonstrüksiyon güvenli midir? 5 yıllık tek merkez onkolojik sonuçlar(2022-09-18) UĞURLU, MUSTAFA ÜMİT; AKMERCAN, AHMET; SAÇAK, BÜLENT; AKDENİZ DOĞAN, ZEYNEP DENİZ; KAYA, HANDAN; BUĞDAYCI, ONUR; GÜLLÜOĞLU, MAHMUT BAHADIR; UĞURLU M. Ü., AKMERCAN A., SAÇAK B., AKDENİZ DOĞAN Z. D., HAYTAOĞLU A. A., KAYA H., BUĞDAYCI O., AKIN TELLİ T., ÖZGEN Z., GÜLLÜOĞLU M. B.Publication Metadata only Meme Kanserinde IGFBP5 yüksek ekspresyonu ile ilişkili gen ekspresyon profili(2015-10-27) PEKER EYÜBOĞLU, İREM; GÜLLÜOĞLU, MAHMUT BAHADIR; KAYA, HANDAN; AKKİPRİK M., PEKER EYÜBOĞLU İ., ÖZMEN T., GÜLLÜ AMURAN G., GÜLLÜOĞLU M. B., KAYA H., ÖZER S. A.Publication Metadata only Clinical outcome of breast cancer patients with N3a (>= 10 positive lymph nodes) disease: has it changed over years?(HUMANA PRESS INC, 2011) DANE, FAYSAL; Basaran, Gul; Devrim, Cabuk; Caglar, Hale B.; Gulluoglu, Bahadir; Kaya, Handan; Seber, Selcuk; Korkmaz, Taner; Telli, Ferhat; Kocak, Muharrem; Dane, Faysal; Yumuk, Fulden P.; Turhal, Serdar N.It has been shown that breast cancer patients with N3a (10 positive lymph nodes) had a poor prognosis. We planned to investigate the clinical outcome BC patients who presented with N3a disease and had no evidence of systemic metastasis at the time of diagnosis. We made a retrospective chart review of breast cancer patients who had a parts per thousand yen10 positive lymph nodes and received adjuvant systemic therapy in Marmara University Hospital between 1998 and 2008. We recorded clinical, pathologic and treatment characteristics of the patients and analyzed the survival outcome. We identified 73 patients with N3a disease who were treated in Marmara University Hospital between 1998 and 2008. The median age was 52. Most (75%) of the patients had invasive ductal histology, 75% had T2/T3 tumors, 36% had grade 3 tumors. The median number of metastatic lymph nodes was 15. Estrogen and progesterone receptors were both positive in 61% and both negative in 16+ tumors. Her-2/neu status was assessed in 68% of the tumors; 18% of patients had 3+ and 50% had negative scores. Six patients had triple negative tumors. All patients except one received adjuvant chemotherapy and radiotherapy. Seventy-four percent of patients received anthracycline/taxane-based chemotherapy. Fifty-nine patients received adjuvant endocrine therapy, 42% them received aromatase inhibitors. Five of the 13 Her-2 positive patients received adjuvant trastuzumab. With a median follow-up of 47 months, 5-year disease and overall survival rates were 66 and 81%, respectively. Twenty-four patients had relapsed and 14 patients died. Her-2 status and the number of lymph nodes (< 20 vs. a parts per thousand yen20) had significant impact on disease-free survival in the univariate analysis (P = 0.03 and 0.05, respectively) and Her-2 retained its significant impact on disease-free survival in the multivariate analysis (P = 0.05). The prognosis of BC patients with N3a disease has changed favorably in the past decade with the current standards of care.Publication Metadata only Neoadjuvan kemoterapi sonrası meme koruyucu cerrahide marjin pozitifligi ve reeksizyon oranları(2022-03-23) UĞURLU, MUSTAFA ÜMİT; AKMERCAN, AHMET; KAYA, HANDAN; BUĞDAYCI, ONUR; GÜLLÜOĞLU, MAHMUT BAHADIR; UĞURLU M. Ü., AKMERCAN A., KAYA H., BUĞDAYCI O., YUMUK P. F., GÜLLÜOĞLU M. B.Publication Metadata only Conventional tools for predicting satisfactory response to neoadjuvant chemotherapy in HR+/HER2- breast cancer patients(2023-10-01) GÜLLÜOĞLU, MAHMUT BAHADIR; EREN, ÖZGÜR CAN; KAYA, HANDAN; UĞURLU, MUSTAFA ÜMİT; Oprea A. L., GÜLLÜOĞLU M. B., Aytin Y. E., EREN Ö. C., Aral C., Szekely T. B., TAŞTEKİN E., KAYA H., BADEMLER S., Karanllk H., et al.Aim: The aim of the study was to assess the role of Magee Equation 3 (MagEq3), IHC4 score, and HER2-low status in predicting \"satisfactory response (SR)\"to neoadjuvant chemotherapy (NAC) in HR+/HER2- breast cancer (BC) patients. Methods: In a retrospective study, female patients of any age with T1-4, N0-2, M0 HR+/HER2- BC who received NAC and underwent adequate locoregional surgical treatment were included. Patients were grouped according to 2 outcomes: (a) overall response to NAC in breast and axilla by using residual cancer burden (RCB) criteria and (b) axillary downstaging after NAC by using N staging. 2 cohorts for overall response were overall SR (RCB 0-1) and no SR (RCB 2-3). On the other hand, for axillary downstaging, 2 cohorts constituted from axillary SR (ypN0 and ypN0i+) and no SR (ypNmic-N3). MagEq3 and IHC4 scores were calculated from their pathological tumor slides in each patient. HER2 status was categorized as either \"no\"or \"low.\"In addition, patient age, family history, tumor histology, stage at admission, and Ki-67 status were compared between cohorts according to predefined outcomes. Results: In a total of 230 BC patients, 228 patients were included to compare according to their RCB levels. The mean age of patients with overall SR was significantly lower than those without. Patients with high Ki-67 expression, high (>30) MagEq3 score, high ICH4 quartile, and HER2-low status had significantly more overall SR. On the other hand, only patients with high Ki-67 expression had significantly more axillary SR. MagEq3 score levels, ICH4 quartiles, and HER2 status were similar between patients with axillary SR and not. Conclusion: MagEq3 and IHC4 tools seemed to be useful to predict those HR+/HER2- BC patients who are most likely to get benefit from NAC. But, only high Ki-67 expression level significantly predicted satisfactory axillary downstaging in HR+/HER2- BC patients.Publication Metadata only Meme kanserinde PIK3CA gen mutasyonlarının hrm yöntemiyle belirlenmesi ve IGFBP-5 ekspresyonu düzeyi ile ilişkisi(2014-04-23) PEKER EYÜBOĞLU, İREM; GÜLLÜOĞLU, MAHMUT BAHADIR; KAYA, HANDAN; DİRİCAN E., KAYA Z., GÜLLÜ AMURAN G., PEKER EYÜBOĞLU İ., ÖZMEN T., GÜLLÜOĞLU M. B., KAYA H., ÖZER S. A., AKKİPRİK M.Publication Metadata only Treatment outcomes of breast cancer patients older than 65 years old received local radiotherapy(2014-09-30) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; YUMUK, PERRAN FULDEN; UĞURLU, MUSTAFA ÜMİT; KAYA, HANDAN; GÜLLÜOĞLU, MAHMUT BAHADIR; Atasoy B. M., Kefeli A., Özgen Z., Rzayev R., Yumuk P. F., Uğurlu M. Ü., Kaya H., Arıbal M. E., Güllüoğlu M. B.